Thelansis

 Recurrent vulvovaginal candidiasis (RVVC) is characterized by experiencing four or more confirmed episodes of vulvovaginal candidiasis within a year, and it presents a significant challenge in effectively managing this infection. It typically results from a relapse caused by the same persistent strains of C. albicans rather than a new infection caused by different strains. This condition is more likely to develop in environments with elevated estrogen levels and often affects pregnant women. Recurrent thrush is relatively uncommon, affecting approximately 5-8% of women of reproductive age. Yet, it can profoundly impact women's quality of life, leading to symptoms like vulvar itching, soreness, painful urination, painful intercourse, and the characteristic "cottage cheese-like" vaginal discharge. Primary RVVC is considered idiopathic, as its underlying predisposing factors are unknown. It occurs in otherwise healthy, immunocompetent women, most of whom do not have identif...

 Recurrent vulvovaginal candidiasis (RVVC) is characterized by experiencing four or more confirmed episodes of vulvovaginal candidiasis within a year, and it presents a significant challenge in effectively managing this infection. It typically results from a relapse caused by the same persistent strains of C. albicans rather than a new infection caused by different strains. This condition is more likely to develop in environments with elevated estrogen levels and often affects pregnant women. Recurrent thrush is relatively uncommon, affecting approximately 5-8% of women of reproductive age. Yet, it can profoundly impact women's quality of life, leading to symptoms like vulvar itching, soreness, painful urination, painful intercourse, and the characteristic "cottage cheese-like" vaginal discharge. Primary RVVC is considered idiopathic, as its underlying predisposing factors are unknown. It occurs in otherwise healthy, immunocompetent women, most of whom do not have identif...

 Recurrent vulvovaginal candidiasis (RVVC), usually defined as four or more episodes of symptomatic VVC within 1 year, affects a small percentage of women (<5%). The pathogenesis of RVVC is poorly understood, and most women with RVVC have no apparent predisposing or underlying conditions. C. glabrata and other nonalbicans Candida species are observed in 10%–20% of women with RVVC. According to Thelansis disease modeling data and systematic literature review, the prevalence of RVVC is ~5% to 12% in the US and Europe. Thelansis’s “Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis (RVVC) treatment modaliti...